143 related articles for article (PubMed ID: 37054917)
1. Utility of the Khorana and the new-Vienna CATS prediction scores in cancer patients of the HYPERCAN cohort.
Verzeroli C; Giaccherini C; Russo L; Bolognini S; Gamba S; Tartari CJ; Schieppati F; Ticozzi C; Vignoli A; Masci G; Sarmiento R; Spinelli D; Malighetti P; Tondini C; Petrelli F; Giuliani F; D'Alessio A; Gasparini G; Minelli M; De Braud F; Santoro A; Labianca R; Marchetti M; Falanga A;
J Thromb Haemost; 2023 Jul; 21(7):1869-1881. PubMed ID: 37054917
[TBL] [Abstract][Full Text] [Related]
2. Assessing the risk of venous thromboembolism in patients with haematological cancers using three prediction models.
El-Sayed HA; Othman M; Azzam H; Bucciol R; Ebrahim MA; El-Agdar MAMA; Tera Y; Sakr DH; Ghoneim HR; Selim TE
J Cancer Res Clin Oncol; 2023 Dec; 149(20):17771-17780. PubMed ID: 37935936
[TBL] [Abstract][Full Text] [Related]
3. A New Risk Prediction Model for Venous Thromboembolism and Death in Ambulatory Lung Cancer Patients.
Gomez-Rosas P; Giaccherini C; Russo L; Verzeroli C; Gamba S; Tartari CJ; Bolognini S; Ticozzi C; Schieppati F; Barcella L; Sarmiento R; Masci G; Tondini C; Petrelli F; Giuliani F; D'Alessio A; Minelli M; De Braud F; Santoro A; Labianca R; Gasparini G; Marchetti M; Falanga A; On Behalf Of The Hypercan Investigators
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760562
[TBL] [Abstract][Full Text] [Related]
4. Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer.
Mansfield AS; Tafur AJ; Wang CE; Kourelis TV; Wysokinska EM; Yang P
J Thromb Haemost; 2016 Sep; 14(9):1773-8. PubMed ID: 27273134
[TBL] [Abstract][Full Text] [Related]
5. Venous Thromboembolism Is an Independent Predictor of Mortality Among Patients with Gastric Cancer.
Fuentes HE; Oramas DM; Paz LH; Wang Y; Andrade XA; Tafur AJ
J Gastrointest Cancer; 2018 Dec; 49(4):415-421. PubMed ID: 28634671
[TBL] [Abstract][Full Text] [Related]
6. Comparison among three predictive models for cancer-associated thromboembolism in a hispanic population.
Ramos-Esquivel A; Marenco-Flores A; Hernández-Romero G; Céspedes-Calvo A; Mora-Hidalgo R
J Thromb Thrombolysis; 2023 Oct; 56(3):433-438. PubMed ID: 37407771
[TBL] [Abstract][Full Text] [Related]
7. Identification of risk factors for venous thromboembolism and evaluation of Khorana venous thromboembolism risk assessment in Japanese lung cancer patients.
Hiraide M; Shiga T; Minowa Y; Nakano Y; Yoshioka H; Suzuki K; Yasuda C; Takahashi H; Hama T
J Cardiol; 2020 Jan; 75(1):110-114. PubMed ID: 31416782
[TBL] [Abstract][Full Text] [Related]
8. Using the Khorana risk score to predict venous thromboembolism and overall survival in a cohort of Hispanic patients with solid malignancies.
Ramos-Esquivel A; Marenco-Flores A; Hernández-Romero G; Umaña-Mora C; Céspedes-Calvo A; Mora-Hidalgo R
Ecancermedicalscience; 2022; 16():1470. PubMed ID: 36819798
[TBL] [Abstract][Full Text] [Related]
9. Performance of Khorana Risk Score for Prediction of Venous Thromboembolism in Patients With Hepatocellular Carcinoma.
Wang Y; Attar BM; Fuentes HE; Yu J; Zhang H; Tafur AJ
Clin Appl Thromb Hemost; 2018 Apr; 24(3):471-476. PubMed ID: 28288526
[TBL] [Abstract][Full Text] [Related]
10. High plasma levels of soluble P-Selectin and Factor VIII predict venous thromboembolism in non-small cell lung cancer patients: The Thrombo-Nsclc risk score.
Castellón Rubio VE; Segura PP; Muñoz A; Farré AL; Ruiz LC; Lorente JA
Thromb Res; 2020 Dec; 196():349-354. PubMed ID: 32977135
[TBL] [Abstract][Full Text] [Related]
11. Validation of the Khorana Venous Thromboembolism Risk Score in Japanese Cancer Patients.
Akasaka-Kihara F; Sueta D; Ishii M; Maki Y; Hirakawa K; Tabata N; Ito M; Yamanaga K; Fujisue K; Hoshiyama T; Hanatani S; Kanazawa H; Takashio S; Arima Y; Araki S; Usuku H; Nakamura T; Suzuki S; Yamamoto E; Soejima H; Kaikita K; Matsushita K; Matsuoka M; Usuku K; Tsujita K
JACC Asia; 2021 Sep; 1(2):259-270. PubMed ID: 36338156
[TBL] [Abstract][Full Text] [Related]
12. A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts.
Muñoz A; Ay C; Grilz E; López S; Font C; Pachón V; Castellón V; Martínez-Marín V; Salgado M; Martínez E; Calzas J; Ortega L; Rupérez A; Salas E; Pabinger I; Soria JM
J Clin Oncol; 2023 Jun; 41(16):2911-2925. PubMed ID: 36730884
[TBL] [Abstract][Full Text] [Related]
13. A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts.
Pabinger I; van Es N; Heinze G; Posch F; Riedl J; Reitter EM; Di Nisio M; Cesarman-Maus G; Kraaijpoel N; Zielinski CC; Büller HR; Ay C
Lancet Haematol; 2018 Jul; 5(7):e289-e298. PubMed ID: 29885940
[TBL] [Abstract][Full Text] [Related]
14. Prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies: validation of the Khorana Risk Score.
Rupa-Matysek J; Gil L; Kaźmierczak M; Barańska M; Komarnicki M
Med Oncol; 2017 Dec; 35(1):5. PubMed ID: 29209847
[TBL] [Abstract][Full Text] [Related]
15. Biomarker-enhanced VTE risk stratification in ambulatory patients with cancer.
Shaw JR; Kumar V; Mallick R; Carrier M; Ilich A; Key NS; Wells P
Thromb Res; 2020 Dec; 196():437-443. PubMed ID: 33065408
[TBL] [Abstract][Full Text] [Related]
16. Assessing the risk of venous thromboembolism (VTE) in ambulatory patients with cancer: Rationale and implementation of a pharmacist-led VTE risk assessment program in an ambulatory cancer centre.
Pelletier R
J Oncol Pharm Pract; 2021 Jun; 27(4):911-918. PubMed ID: 33757321
[TBL] [Abstract][Full Text] [Related]
17. Risk stratification for the development of venous thromboembolism in hospitalized patients with cancer.
Parker A; Peterson E; Lee AYY; de Wit C; Carrier M; Polley G; Tien J; Wu C
J Thromb Haemost; 2018 Jul; 16(7):1321-1326. PubMed ID: 29733498
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Biomarkers for the Prediction of Venous Thromboembolism in Ambulatory Cancer Patients.
Schorling RM; Pfrepper C; Golombek T; Cella CA; Muñoz-Unceta N; Siegemund R; Engel C; Petros S; Lordick F; Knödler M
Oncol Res Treat; 2020; 43(9):414-427. PubMed ID: 32580190
[TBL] [Abstract][Full Text] [Related]
19. Growth differentiation factor-15 and prediction of cancer-associated thrombosis and mortality: a prospective cohort study.
Nopp S; Moik F; Kraler S; Englisch C; Preusser M; von Eckardstein A; Pabinger I; Lüscher TF; Ay C
J Thromb Haemost; 2023 Sep; 21(9):2461-2472. PubMed ID: 37192696
[TBL] [Abstract][Full Text] [Related]
20. Comparison between the Khorana prediction score and Caprini risk assessment models for assessing the risk of venous thromboembolism in hospitalized patients with cancer: a retrospective case control study.
Hu Y; Li X; Zhou H; Lin P; Zhang J; Huang D; Qi M; Tang Y; Yi Q; Liang Z; Wang M
Interact Cardiovasc Thorac Surg; 2020 Oct; 31(4):454-460. PubMed ID: 32910201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
